References
- European Medicines Agency. European Public Assessment Report (EPAR) - product information, Forsteo® (Teriparatide) [Internet]; 2020 cited 2021 Jun 4. Available from: https://www.ema.europa.eu/en/documents/product-information/forsteo-epar-product-information_en.pdf.
- U.S. Food and Drug Administration. Prescribing information, Forteo® (Teriparatide injection) [Internet]; 2020 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318Orig1s054lbl.pdf.
- U.S. Food and Drug Administration. Prescribing information, Bonsity® (Teriparatide injection) [Internet]; 2019. cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211939s000lbl.pdf
- European Medicines Agency. European Public Assessment Report (EPAR) - Product information, Terrosa® (Teriparatide) [Internet]; 2020 cited 2021 Jun 4. Available from: https://www.ema.europa.eu/en/documents/product-information/terrosa-epar-product-information_en.pdf.
- European Medicines Agency. European Public Assessment Report (EPAR) - product information, Movymia® (Teriparatide) [Internet]; 2021. cited 2021 Jun 4. Available from: https://www.ema.europa.eu/en/documents/product-information/movymia-epar-product-information_en.pdf.
- International Organization for Standardization (ISO). ISO 11608-3:2000. Pen-injectors for medical use - Part 3: finished cartridges - Requirements and test methods [Internet]; 2000 cited 2021 Jun 10. Available from: https://www.iso.org/standard/24228.html.
- International Organization for Standardization (ISO). ISO 11608-1:2014. Needle-based injection systems for medical use - Requirements and test methods - Part 1: needle-based injection systems [Internet]; 2014 cited 2021 Jun 6. Available from: https://www.iso.org/standard/65021.html.
- European Medicines Agency. Good practice guide on risk minimisation and prevention of medication errors [Internet]; 2015 cited 2021 Jun 4. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf.
- U.S. Food and Drug Administration. Applying human factors and usability engineering to medical devices: guidance for industry and FDA staff [Internet]; 2016 cited 2021 Jun 4. Available from: https://www.fda.gov/media/80481/download.
- U.S. Food and Drug Administration. Human factors studies and related clinical study considerations in combination product design and development: draft guidance for industry and FDA Staff [Internet]; 2016 cited 2021 Jun 4. Available from: https://www.fda.gov/media/96018/download.
- International Organization for Standardization (ISO). IEC 62366-1:2015. Medical devices - Part 1: application of usability engineering to medical devices [Internet]; 2015 cited 2021 Jun 4. Available from: https://www.iso.org/standard/63179.html.
- International Organization for Standardization (ISO). IEC/TR 62366-2:2016. Medical devices - Part 2: guidance on the application of usability engineering to medical devices. [Internet]; 2016 cited 2021 Jun 4. Available from: https://www.iso.org/standard/69126.html.
- International Organization for Standardization (ISO). ISO 14917:2012: Medical devices. Application of risk management to medical devices. International Organization for Standardization [Internet]; 2019 cited 2021 Jun 4. Available from: https://www.iso.org/standard/72704.html.
- Gupta SP, Pidgeon A. An analytical approach to identifying potential use-related issues concerning a medical device under development. J Med Eng Technol. 2016;40(3):61–71.
- U.S. Food and Drug Administration. Human factors, label, and labeling review for Basaglar® (Insulin glargine [rDNA origin]) injection, 100 units/mL. NDA 205692. Reference ID: 3485646 [Internet]; 2014 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label, labeling, and human factors results review for Adlyxin® (Lixisenatide) injection, 150 µg/3 mL [50 µg/mL] and 300 µg/3 mL [100 µg/mL]. NDA 208471. Reference ID: 3905867 [Internet]; 2016 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208471Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Review of revised label and labeling for Tymlos® (Abaloparatide) injection 80 µg/40 µl. NDA 208743. Reference ID: 4082122 [Internet]; 2017 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling, human factors and usability review for Natpara® (Recombinant human parathyroid hormone [1-84]) for injection, 25 µg, 50 µg, 75 µg, and 100 µg. BLA 125511. Reference ID: 3491934 [Internet]; 2014 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125511Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factor results and label and labeling review for Aimovig® (Erenumab-aooe) injection, 70 mg/mL auto-injector and prefilled syringe. BLA 761077. Reference ID: 4238517 [Internet]; 2018 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling review for Repatha® (Evolocumab) injection, 140 mg/mL Prefilled syringe] Repatha® SureClick (Evolocumab) injection, 140 mg/mL [Autoinjector]. BLA 125522. Reference ID: 3731106 [Internet]; 2015 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125522Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors, label, and labeling review for Taltz® (Ixekizumab) injection, 80 mg/mL. BLA 125521. Reference ID: 3846313 [Internet]; 2015 cited 2021 Jun 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000OtherRedt.pdf.
- Patel R, Mehta M, Dahiya M, et al. A review of use errors reported in human factor validation studies of biological combination products. J Med Eng Technol. 2021:2; 1–11.
- Patel R, Mehta M, Pipalava P, et al., Insights into human factor studies conducted for US FDA-approved biological combination products. Expert Opin Drug Deliv. 16(12): 1333–1353. 2019.